CA-NEXON-AMERICA
16.12.2021 23:05:06 CET | Business Wire | Press release
MapleStory M , Nexon’s popular free-to-play mobile MMORPG, has officially launched its latest update, bringing the long-awaited Pathfinder class to the game alongside a flurry of winter season events and activities for Maplers to tackle. The Pathfinder update has also increased the max level to 250, and brings new daily and weekly missions, achievements, and a new mini-dungeon to the game.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006140/en/
As of today, the sharpshooting Explorer who wields an ancient bow, Pathfinder, is available as a new playable class. Maplers who pre-registered their Pathfinder were eligible for items such as Auto Battle Charge Tickets and EXP tickets, while all players can take part in Mega Burning and On-Time/Growth Support events to help level-up a new Pathfinder quickly. As a bonus after today’s maintenance, both MapleStory M and MapleStory will be running the Pathfinder Link Event through January 19, 2022, whereby, after reaching level, 70, 120, and 140 on MapleStory M with the Pathfinder, Maplers can garner rewards in both games, including a Pathfinder outfit gift box, Ancient Relic, and more.
The Black Mage's fourth commander, Arkarium, formerly a servant under Rhinne, Maple World's Transcendent of Time, makes his debut in MapleStory M . Maplers will be able to craft all-new boss accessory Dominator Pendant using the materials acquired when defeating Arkarium.
A new map in the Arcane River has also been added, the Dreaming City Lachelein , bringing with it new quests, monsters, area items to discover, and a new Arcane force field. Mini-dungeons have also received a quality of life improvement with this update so that Maplers can auto-play multiple times by using tickets and mesos.
In addition to the events celebrating the arrival of Pathfinder, players can look forward to numerous winter seasonal events occurring throughout December and into the new year:
- I&B Burning Challenge Mission Event - From December 15, 2021 through January 19, 2022, this event returns, granting not only Ice Agent or Burning Agent player titles, but also granting daily missions for players to conquer.
- Holiday Mr. Kim’s Gift - From December 22 through December 30, 2021, tapping on Mr. Kim will reward players with special items.
-
Winter Happyville
Events
- (Various scheduled times - refer to in-game event banner or see MapleStoryM
patch notes for exact times and dates for each event.) Winter Happy Village will play host to multiple winter events throughout December and January :
- Coin Drop Event
- A Well-Behaved Child Needs A Gift!
- A Crying Child Also Needs A Gift!
- Buff Tree Event
- Great Rudolph Escape
- 2022 Countdown Event - From December 23, 2021 through January 6, 2022, players can enter the event map every day and receive EXP for ten minutes. After spending ten minutes on the map, these players will receive a countdown reward and, on January 1, Maplers can earn a special New Year reward!
- Snowflake Snowpark - From January 6 through January 18, 2022, Maplers can earn AB tickets, EXP tickets, and Gold Leaf by clearing different missions and receiving stamps.
- 2022 New Year Wheel - From January 13 through January 27, 2022, players can receive a maximum of 5 wheel tickets per day by hunting. Rewards for participating in the event include AB tickets, Luckyday scroll 5%, cubes, EXP tickets, and more.
To learn more about MapleStory M, visit the App Store or Google Play Store page and follow @PlayMapleM on Twitter for the latest updates.
Assets: Artwork
Social Media: Facebook / Instagram / Twitter / Twitch / YouTube / Discord
About MapleStory M https://maplestorym.nexon.com/
MapleStory M , launched globally on July 24, 2018, brings the nostalgic world of side-scrolling MMORPG MapleStory to mobile, offering the same endless amount of customization, immersive storylines and epic boss raids that fans have come to expect from the legendary franchise. MapleStory M quickly reached 10 million downloads within 100 days after global launch and recently celebrated its 3-year anniversary with 16 million global downloads.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216006140/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom